Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jun 11, 2020
Open Peer Review Period: Jun 11, 2020 - Aug 6, 2020
Date Accepted: Oct 8, 2021
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Collaborative Research and Development of a Novel, Patient-Centered Digital Platform (MyEyeSite) for Rare Inherited Retinal Disease Data: Acceptability and Feasibility Study

Gilbert R, Sumodhee D, Pontikos N, Hollyhead C, Patrick A, Scarles S, Van Der Smissen S, Nettleton N, Cammack J, Webster AR

Collaborative Research and Development of a Novel, Patient-Centered Digital Platform (MyEyeSite) for Rare Inherited Retinal Disease Data: Acceptability and Feasibility Study

JMIR Form Res 2022;6(1):e21341

DOI: 10.2196/21341

PMID: 35099396

PMCID: 8845013

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

MyEyeSite: Bringing ownership of eye health data into ‘focus’ for patients with inherited retinal diseases (IRD)

  • Rose Gilbert; 
  • Dayyanah Sumodhee; 
  • Nikolas Pontikos; 
  • Catherine Hollyhead; 
  • Angus Patrick; 
  • Sam Scarles; 
  • Sabrina Van Der Smissen; 
  • Nick Nettleton; 
  • Jocelyn Cammack; 
  • Andrew R Webster

ABSTRACT

Background and aims: MyEyeSite is an early stage research collaboration between Moorfields Eye Hospital NHS Trust, Loft Digital, and UCL Institute of Ophthalmology, aiming to design and develop a digital platform for people with rare inherited retinal diseases (IRD), allowing patients, doctors and scientists to share specialist eye health data. The proposed infrastructure will greatly augment research by pooling this highly specific data, from consented patients, thereby quantifying patients’ conditions and accelerating research, by facilitating the planning of disease-specific trials to develop cost-effective treatments, such as gene therapies.

Methods:

Pilot feasibility study, informed by qualitative (focus groups and workshops) and quantitive data (survey) from IRD patient engagement activities involving fifty, and eight-two, participants, respectively.

Results:

82% of participants with IRD were motivated to have a more active role in their eyecare, and share their data for research purposes using a secure technology, such as an app. Our IRD focus group sample, highlighted themes of “frustration with the current system” regarding data sharing within the NHS and positive “expectations” of the potential benefits of the MyEyeSite app and ability to access data via the app, whilst also voicing concerns about data security and potentially unethical use of data by people, outside the NHS, with commercial interests.

Conclusions:

MyEyeSite has the potential to connect groups of patients with similar conditions and uniquely valuable datasets, to commercial research projects and clinical trials which have potential to restore sight and transform lives. This strategy will allow a centralised database of genetic variants contributing to rare disease research.


 Citation

Please cite as:

Gilbert R, Sumodhee D, Pontikos N, Hollyhead C, Patrick A, Scarles S, Van Der Smissen S, Nettleton N, Cammack J, Webster AR

Collaborative Research and Development of a Novel, Patient-Centered Digital Platform (MyEyeSite) for Rare Inherited Retinal Disease Data: Acceptability and Feasibility Study

JMIR Form Res 2022;6(1):e21341

DOI: 10.2196/21341

PMID: 35099396

PMCID: 8845013

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.